Biotech Beast (@Biotech_Beast) profile picture

Pharmacologist and biotech trader. Focus on trading around biotech catalysts. Tweets are not investment advice. May have a position in names I tweet about.

Joined November 2017
I remain long $VIR with the company headed towards its first phase 3 result in hepatitis delta this quarter. The recent $GILD deal in the second in 2026 connected to their PRO-XTEN masking technology, showing the value of that platform.
1
6
985
While $VIR's competitor $MIRM has already reported a phase 3 result in hepatitis delta from its monoclonal antibody, I believe VIR's antibody + siRNA will perform even better in hepatitis delta, given prior phase 2 data. seekingalpha.com/article/495…
1
454
$INCY abstracts from ESMO show its KRAS G12D inhibitor is in the fight with $RVMD's zoldonrasib in PDAC (both running phase 3's) and $VSTM's VS-7375 (competitive CRC data). (I'm long VSTM)
2
1
5
1,439
Also encouraging is $INCY's '890 compound, a next-gen immunotherapy with activity in MSS CRC, even in liver metastasis. Compare that to say $AGEN's bot/bal, where activity is predominantly in non-liver metastasis patients. I took a look here. seekingalpha.com/article/495…
1
485
$VSTM (long). Upcoming catalyst on October 14 is updated data from a trial of VS-7375, an oral KRAS G12D inhibitor. The same drug is under development by GenFleet Therapeutics in China, who are reporting an update from their drug on October 15.
1
1
9
1,345
There's an underlying commercial story there too with $VSTM, the company markets Avmapki Fakzynja Co-pack (avutometinib with defactinib) for LGSOC patients. That product is only a year into its launch, so doesn't yet offset expenses.
1
416
$CNTB (Long). I like the data today, a drug that can reduce treatment-failure following exacerbation in COPD could become part of therapy. Recall the recent story of the COPD drug ensifentrine from $VRNA, who got bought out by $MRK for $10B following its launch.
1
1
1,088
$DERM is in a nice upward channel since lows in late March. Still holding the name, I expect it to perform over time with Emrosi sales continuing to ramp.
1
5
651
$FATE is already underway on a potentially registrational phase 2 trial of its off-the-shelf cell therapy, FT819, for lupus nephritis.
1
3
740
$SYRE's recent data with SPY072, an anti-TL1A, in rheumatoid arthritis were a bit disappointing. The company has two more shots on goal in Q4'26 with '072 with readouts in psoriatic arthritis and axial spondyloarthritis.
602
Remember Geron? After lackluster sales performance in 2025, $GERN has produced Rytelo sales growth in 2026, with Q2'26's $57.5M in net product revenues a 11% increase from Q1'26. Management has guided however, for growth to be backloaded in 2026, so further growth may be ahead.
1
7
1,397
Remember pemvidutide? $ALT has initiated its phase 3 in MASH even as $RHHBY $GSK $NVO are ahead with FGF21's, incretins are already on the market (sema approved, tirz in phase 3) and $MDGL's THRbeta agonist is too.
2
1
4
5,442
I do think $ALT's pemvidutide could have something to add to the mix with its differentiated profile, but a phase 3 result is years away. There is phase 2 data in 2027 for alcohol-associated liver disease, however. seekingalpha.com/article/493…
3
846
$MDGL has built itself a pipeline of MASH drugs, with the CEO speaking about quickly progressing or failing those drugs based on Rezdiffra combo results in MASH. As for competition, a near-term readout is Q4'26 data from $NVO's efruxifermin.
3
595
$TARS (I'm long) Q1'26 net product sales of Xdemvy were down from Q4'25. Up to this point in the Xdemvy launch, each quarter had beaten the prior quarter, despite seasonal variation. Nonetheless, script numbers and comments from the CFO suggest a strong Q2'26 rebound.
1
591
The iRenix acquisition has been met with a lukewarm reaction for $TARS. A phase 3 trial of ocular antiseptic, IRX-101, will provide a readout further down the track (2028) and the opportunity to bring in revenues beyond lotilaner.
373